Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Medizinische Hochschule Hannover has 9 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 9 distinct examiners, showing that each pending case is under the review of a different official. This distribution indicates a diverse array of biological or pharmaceutical innovations being pursued by the institution.
The portfolio's prosecution occurs across 7 distinct art units. This variety suggests that the institution's filings cover several different specialized niches within the biotechnology sector. SPENCE, JENNIFER SUZANNE is the busiest examiner for this portfolio, currently overseeing 1 pending office action. Because the busiest examiner pending count is 1, the 9 pending office actions are spread evenly across the 9 distinct examiners.
Practitioners should be aware that the 9 pending office actions are subject to the interpretations of 7 distinct art units. This requires a strategy that accounts for the different examination cultures and prior art databases used by these seven groups. Since no single examiner manages more than 1 pending action, the institution's success is tied to the individual outcomes of nine separate examination processes.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (38%) |
| §103 only | 2 (25%) |
| §112 only | 2 (25%) |
| Multi-statute (no §101) | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SPENCE, JENNIFER SUZANNE | 1 | 66.9% | +46.0% |
| CORNELIUS, CLAIRE ADRIENNE | 1 | 66.7% | +0.0% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| GONZALES, JOSEPHINE MARIA | 1 | 26.6% | +38.4% |
| LI, RUIXIANG | 1 | 59.5% | +18.6% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.5% |
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.2% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17615453 | COMPOSITIONS AND PROCESS FOR INTEGRATING CELLS INTO EPITHELIUM | PENNINGTON, KATIE LEIGH | 99d overdue |
| 18720993 | ALPHARETROVIRUS-BASED PARTICLES FOR DELIVERY OF RNA INTO CELLS | SPENCE, JENNIFER SUZANNE | — |
| 18289787 | GLYCOPROTEINS FOR PSEUDOTYPING RETROVIRAL VECTOR PARTICLES | CORNELIUS, CLAIRE ADRIENNE | — |
| 18010340 | PROCESS FOR PRODUCING LIVER CELLS | GONZALES, JOSEPHINE MARIA | — |
| 17605180 | ARTIFICIAL SIGNALLING MOLECULE | WEHBE, ANNE MARIE SABRINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17615453 | COMPOSITIONS AND PROCESS FOR INTEGRATING CELLS INTO EPITHELIUM | PENNINGTON, KATIE LEIGH | 99d overdue |
| 17811995 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | KAPUSHOC, STEPHEN THOMAS | 28d overdue |
| 18720993 | ALPHARETROVIRUS-BASED PARTICLES FOR DELIVERY OF RNA INTO CELLS | SPENCE, JENNIFER SUZANNE | — |
| 18010340 | PROCESS FOR PRODUCING LIVER CELLS | GONZALES, JOSEPHINE MARIA | — |
| 17927420 | ADENOVIRUS FOR ANTI-TUMOUR THERAPY | LI, RUIXIANG | — |
| 17605180 | ARTIFICIAL SIGNALLING MOLECULE | WEHBE, ANNE MARIE SABRINA | — |
| Art Unit | Apps |
|---|---|
| 1634 | 2 |
| 1672 | 1 |
| 1636 | 1 |
| 1631 | 1 |
| 1674 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720993 | ALPHARETROVIRUS-BASED PARTICLES FOR DELIVERY OF RNA INTO CELLS | SPENCE, JENNIFER SUZANNE | — | §101§103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18289787 | GLYCOPROTEINS FOR PSEUDOTYPING RETROVIRAL VECTOR PARTICLES | CORNELIUS, CLAIRE ADRIENNE | 1672 | §101§102§103§112 | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18254669 | LENTIVIRAL VECTOR TECHNOLOGY FOR INNER EAR GENE THERAPY | YU, DELPHINUS DOU YI | 1636 | §103 | Final Rejection | — | Pending | May 26, 2023 |
| 18010340 | PROCESS FOR PRODUCING LIVER CELLS | GONZALES, JOSEPHINE MARIA | 1631 | §101§103§112 | Final Rejection | — | Pending | Dec 14, 2022 |
| 17927420 | ADENOVIRUS FOR ANTI-TUMOUR THERAPY | LI, RUIXIANG | 1674 | §112 | Final Rejection | — | Pending | Nov 23, 2022 |
| 17811995 | LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY | KAPUSHOC, STEPHEN THOMAS | 1683 | §112 | Final Rejection | 28d overdue | Pending | Jul 12, 2022 |
| 17615453 | COMPOSITIONS AND PROCESS FOR INTEGRATING CELLS INTO EPITHELIUM | PENNINGTON, KATIE LEIGH | 1634 | §103 | Non-Final OA | 99d overdue | Pending | Nov 30, 2021 |
| 17605180 | ARTIFICIAL SIGNALLING MOLECULE | WEHBE, ANNE MARIE SABRINA | 1634 | §103§112 | Non-Final OA | — | Pending | Oct 20, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial